NAFDAC has issued an alert regarding counterfeit breast cancer drug Phesgo circulating in Nigeria, emphasizing health risks tied to specific batch numbers linked to multiple countries.
The National Agency for Food and Drug Administration and Control (NAFDAC) in Nigeria has issued a crucial warning about the circulation of counterfeit Phesgo 600mg, a drug used in breast cancer treatment. The alert follows a report from Roche, the marketing authorization holder, which indicated concerns centered around two batch numbers, B2346B16 and C3809C5. These counterfeit products have been tied to at least four confirmed cases in Nigeria and other countries, such as Turkey and the Philippines, indicating a wider problem of counterfeit medications.
Reports have surfaced from the Lagos University Teaching Hospital (LUTH-NSIA) where medical professionals have encountered patients who brought in these suspicious products. The counterfeit drugs' presence raises significant concerns about patient safety and the integrity of drug distribution in Nigeria, a nation already grappling with challenges related to drug authenticity and availability.
NAFDAC's warning serves to inform healthcare providers and the public alike to be vigilant regarding counterfeit medications. With the potential risks posed by ingesting unverified drugs, this alert not only highlights the importance of regulatory oversight but also the need for stricter monitoring of drug imports and better public awareness initiatives in the fight against counterfeit pharmaceuticals.
